Price · as of 2026-09-04
$13.77
Market cap 516.45M
Price history
| Week | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 27, 2025 – Oct 31, 2025 | $19.00 | $20.86 | $15.00 | $16.92 | 0 |
| Nov 3, 2025 – Nov 7, 2025 | $17.00 | $17.56 | $14.00 | $15.61 | 0 |
| Nov 10, 2025 – Nov 14, 2025 | $15.73 | $16.19 | $13.33 | $14.09 | 0 |
| Nov 17, 2025 – Nov 21, 2025 | $13.90 | $15.38 | $13.20 | $13.99 | 0 |
| Nov 24, 2025 – Nov 28, 2025 | $13.80 | $14.32 | $12.24 | $13.63 | 0 |
| Dec 1, 2025 – Dec 5, 2025 | $13.99 | $19.25 | $12.77 | $18.49 | 0 |
| Dec 8, 2025 – Dec 12, 2025 | $18.87 | $21.40 | $18.00 | $20.70 | 0 |
| Dec 15, 2025 – Dec 19, 2025 | $20.51 | $21.55 | $19.21 | $20.55 | 0 |
| Dec 22, 2025 – Dec 26, 2025 | $20.13 | $21.47 | $17.65 | $18.01 | 0 |
| Dec 29, 2025 – Jan 2, 2026 | $18.00 | $18.33 | $15.58 | $16.77 | 0 |
| Jan 5, 2026 – Jan 9, 2026 | $17.11 | $18.99 | $15.78 | $18.02 | 0 |
| Jan 12, 2026 – Jan 16, 2026 | $18.01 | $20.50 | $16.76 | $17.00 | 0 |
| Jan 19, 2026 – Jan 23, 2026 | $17.20 | $19.68 | $16.27 | $17.98 | 0 |
| Jan 26, 2026 – Jan 30, 2026 | $17.98 | $19.34 | $17.06 | $17.69 | 0 |
| Feb 2, 2026 – Feb 6, 2026 | $17.61 | $18.31 | $15.48 | $16.98 | 0 |
| Feb 9, 2026 – Feb 13, 2026 | $16.98 | $18.91 | $16.51 | $17.22 | 0 |
| Feb 16, 2026 – Feb 20, 2026 | $17.22 | $18.17 | $16.91 | $17.88 | 0 |
| Feb 23, 2026 – Feb 27, 2026 | $18.87 | $20.42 | $16.70 | $17.27 | 0 |
| Mar 2, 2026 – Mar 6, 2026 | $17.27 | $18.90 | $16.59 | $18.51 | 0 |
| Mar 9, 2026 – Mar 13, 2026 | $18.51 | $20.25 | $18.38 | $19.07 | 0 |
| Mar 16, 2026 – Mar 20, 2026 | $19.21 | $21.51 | $16.31 | $17.56 | 0 |
| Mar 23, 2026 – Mar 27, 2026 | $18.02 | $19.72 | $16.30 | $18.55 | 0 |
| Mar 30, 2026 – Apr 2, 2026 | $18.22 | $21.76 | $18.02 | $21.17 | 0 |
| Apr 6, 2026 – Apr 10, 2026 | $21.22 | $30.28 | $21.22 | $26.73 | 0 |
| Apr 13, 2026 – Apr 17, 2026 | $26.52 | $31.13 | $24.49 | $30.05 | 0 |
| Apr 20, 2026 – Apr 24, 2026 | $29.85 | $33.28 | $27.00 | $29.76 | 0 |
| Apr 27, 2026 – May 1, 2026 | $29.35 | $32.08 | $28.24 | $30.70 | 0 |
| May 4, 2026 – May 8, 2026 | $30.55 | $30.55 | $26.39 | $27.40 | 0 |
| May 11, 2026 – May 15, 2026 | $27.26 | $31.34 | $27.26 | $28.73 | 0 |
| May 18, 2026 – May 22, 2026 | $28.20 | $29.97 | $25.21 | $28.75 | 0 |
| May 25, 2026 – May 29, 2026 | $28.26 | $30.83 | $28.25 | $29.31 | 0 |
| Jun 1, 2026 – Jun 5, 2026 | $28.99 | $30.93 | $25.66 | $28.01 | 0 |
| Jun 8, 2026 – Jun 12, 2026 | $28.40 | $31.28 | $27.44 | $27.75 | 0 |
| Jun 15, 2026 – Jun 18, 2026 | $27.89 | $30.41 | $26.74 | $28.82 | 0 |
| Jun 22, 2026 – Jun 26, 2026 | $27.98 | $34.37 | $27.98 | $33.28 | 0 |
| Jun 29, 2026 – Jul 2, 2026 | $33.43 | $37.61 | $32.42 | $37.09 | 0 |
| Jul 6, 2026 – Jul 10, 2026 | $37.09 | $40.43 | $34.31 | $39.32 | 0 |
| Jul 13, 2026 – Jul 17, 2026 | $38.46 | $39.28 | $35.28 | $37.87 | 0 |
| Jul 20, 2026 – Jul 24, 2026 | $38.11 | $38.92 | $34.38 | $36.56 | 0 |
| Jul 27, 2026 – Jul 31, 2026 | $12.98 | $16.07 | $9.10 | $13.02 | 0 |
| Aug 3, 2026 – Aug 7, 2026 | $12.85 | $13.74 | $12.08 | $12.17 | 0 |
| Aug 10, 2026 – Aug 14, 2026 | $11.06 | $12.52 | $10.84 | $11.75 | 0 |
| Aug 17, 2026 – Aug 21, 2026 | $11.76 | $12.32 | $10.96 | $11.21 | 0 |
| Aug 24, 2026 – Aug 28, 2026 | $11.21 | $13.24 | $10.51 | $12.60 | 0 |
| Aug 31, 2026 – Sep 4, 2026 | $12.59 | $14.14 | $12.12 | $13.77 | 0 |
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | — | — |
| P/E | -5.21 | |
| P/B | 1.83 | |
| P/S | — | |
| EV/EBITDA | -3.36 | |
| PEG | -5.44 | |
| P/TBV | 1.83 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | |||||
| 2025 | $19.07 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
- CEO
- Christopher A. Kroeger
- Employees
- 133
- Beta
- 2.65
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MPLT | MapLight Therapeutics, In… | $12.17 | 516.45M | — | — | -5.21 | 1.83 | — | -3.36 | -5.44 | 1.83 | 0.00% | 0.00% | 0.00% | -56.19% | -196.55% | -52.29% | 0.01 | — | 20.01 | 18.80 | 0.25 | 95.72% | — | 74.17% | -16.51% | -8.51 | -161.13% | 0.00% | 0.00% | 1.10% | -3.20 | -3.90 | — | 22.38 |
| BRTX | BioRestorative Therapies,… | $0.20 | 1.83M | $7.04 | +3,349% | -0.19 | 7.64 | 7.57 | 0.02 | -0.53 | -15.35 | 93.37% | -4350.05% | -3959.40% | -320.47% | 652.32% | -174.11% | 0.00 | — | 0.84 | 0.80 | 0.11 | 36.21% | -10.30% | 30.81% | -400.33% | -2.90 | 454.62% | 0.00% | 0.00% | 35.36% | 0.01 | 0.02 | -0.64 | -70.61 |
| DWTX | Dogwood Therapeutics, Inc… | $1.81 | 3.45M | — | — | -0.73 | 0.34 | — | -0.55 | — | -3.88 | 0.00% | 0.00% | 0.00% | -49.23% | -41.88% | -37.14% | 0.00 | — | 2.76 | 2.13 | 0.19 | -65.50% | — | 77.67% | -62.09% | -5.11 | -23.39% | 0.00% | 0.00% | 28.23% | -0.67 | -1.20 | — | -1.64 |
| EDSA | Edesa Biotech, Inc. | $5.27 | 50.77M | — | — | -1.39 | 0.80 | — | 0.11 | — | 0.95 | 0.00% | 0.00% | 0.00% | -99.57% | -603.13% | -82.86% | 0.00 | — | 10.67 | 10.60 | 1.53 | -34.20% | — | 49.73% | -73.29% | -6.79 | -558.20% | 0.00% | 0.00% | 97.84% | 0.10 | 0.11 | — | -2.27 |
| ERNA | Ernexa Therapeutics Inc. | $4.21 | 1.32M | $1.74 | -59% | -0.14 | 0.84 | — | -0.05 | -0.34 | 5.65 | 0.00% | 0.00% | 0.00% | -686.69% | -1117.18% | -253.70% | 0.20 | -345.15 | 1.01 | 0.64 | 0.10 | 42.68% | -100.00% | -56.47% | -349.51% | -2.25 | -848.35% | 0.00% | 0.00% | 17.29% | -0.07 | -0.09 | — | -63.86 |
| IMRN | Immuron Limited | $1.03 | 6.65M | $10.16 | +885% | -2.91 | 1.89 | 2.08 | -1.78 | — | 1.89 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -26.23% | 48.63% | 4.36% | -40.45% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.76 | -1.54 | 1.29 | -7.10 |
| LPCN | Lipocine Inc. | $2.13 | 12.36M | $12,561.78 | +589,655% | -4.15 | 2.76 | 20.23 | -2.67 | 0.00 | 2.76 | -334.26% | -524.69% | -487.06% | -54.28% | 3245.49% | -48.73% | 0.03 | — | 6.68 | 5.91 | 0.50 | 105525.00% | -82.35% | 644.34% | -24.41% | -3.86 | 3054.40% | 0.00% | 0.00% | 0.00% | -2.46 | -2.61 | 12.91 | -8.63 |
| OSRH | OSR Holdings, Inc. | $0.44 | 14.67M | $30.80 | +6,853% | -0.12 | 0.03 | 0.72 | -0.25 | -0.02 | -0.02 | 20.40% | -631.01% | -619.82% | -50.63% | -44.95% | -20.76% | 0.06 | -36.22 | 0.16 | 0.13 | -0.14 | 644.44% | -17.69% | 105.87% | -213.83% | -0.25 | -11.79% | 0.00% | 0.00% | 0.00% | -0.26 | -1.07 | 1.65 | -0.71 |
| PMN | ProMIS Neurosciences, Inc… | $14.71 | 19.23M | — | — | -802.80 | -25335.23 | — | -802.65 | — | -25335.23 | 0.00% | 0.00% | 0.00% | -521.61% | 1892.48% | -282.76% | 0.00 | — | 0.88 | 0.59 | 0.15 | -922.18% | — | 3.45% | -0.09% | -2.70 | 1324.80% | 0.00% | 0.00% | 0.00% | -793.69 | -1133.79 | — | 1797.91 |
| TRAW | Traws Pharma, Inc. | $0.53 | 4.86M | $100.19 | +18,732% | 1.79 | -26.16 | 5.90 | -0.71 | — | -5.21 | 100.00% | -640.68% | 328.67% | -56.85% | 62.26% | 51.55% | 0.00 | — | 0.72 | 0.68 | 0.21 | -102.33% | 1134.51% | -30.28% | -126.21% | -1.63 | 72.35% | 0.00% | 0.00% | 14.61% | -0.71 | -0.61 | 4.53 | -89.16 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $13.77) − 1 = — (IC, example).